Merck's Eppatoran在治疗Lupus皮肤症状方面很有前途,导致进一步试验。 Merck's Enpatoran shows promise in treating lupus skin symptoms, leading to further trials.

根据一项2期研究,默克的实验药物Enpatoran在皮肤和全身性红斑狼 (CLE和SLE) 患者的皮肤皮疹减少疾病活动方面显示出有前途的结果. Merck's experimental drug, Enpatoran, has shown promising results in reducing disease activity in patients with cutaneous and systemic lupus erythematosus (CLE and SLE) who have active skin rashes, according to a Phase 2 study. 药物改善了皮肤状况,并得到了良好的缓解,具有可管理的副作用。 The drug improved skin condition and was well-tolerated with manageable side effects. Merck目前正在计划根据这些积极成果进一步开展第三阶段研究。 Merck is now planning for further Phase 3 studies based on these positive outcomes.